About Us

Corporate Overview

Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide.

Preclinical Services Portfolio

At Bridge, we help our clients plan and conduct safety assessment studies to support compound development programs involving small molecules, biologics, neutraceuticals, vaccines, chemicals and intermediates. We conduct both short- and long-term in vivo studies employing everything from acute to carcinogenicity protocols.

• GLP-Compliant Services — general toxicology, safety pharmacology (CV, CNS, respiratory), vaccine development, pathology, bioanalytical, and DMPK

• Species — mice, rats, rabbits, guinea pigs, canines, non-human primates, and minipigs

• Routes of Administration — continuous infusion, dermal, ocular, oral (gavage, capsule, diet, drinking water, etc.), parenteral (I.V., I.M., S.C., I.P., etc.), vaginal, rectal and customized.

Fully Accredited Facilities

• Equivalent SOPs – English only

• Use of Provantis^TM data acquisition software©

• Integrated program management

• US board-certified toxicologists and pathologists

• Global accreditations – GLP-compliant and AAALAC-accredited

• Animal welfare procedures

• Strict confidentiality and data security

• The industry’s top staff technical training and certification program

Highly Qualified, Experienced Staff

Bridge Laboratories has a hard-earned reputation for superior technical expertise, extensive regulatory experience and remarkable speed and flexibility in meeting the needs of its clients. In 2007, for example, we achieved a 100% on-time or early report delivery rate in China. We have been delivering outstanding results to our clients and it all starts with the quality of our staff. All of them share the same client-centered focus and "can do" attitude that extends to every member of the Bridge team and drives every Bridge research project.

The Bridge Advantage: More Choices, Better Service

Bridge offers its clients drug development services to organizations whose research relies on non-human primates or who must, for other reasons, leverage the economies of doing business in the China market. You can be sure of getting the same high-quality services from a drug development partner committed to delivering your research study or other regulatory submission on time, at a competitive price.